Event Highlights

/Event Highlights

Connecticut Synthetic Chemistry Start-Up Uses a Practical Business Model to Develop Drugs

Our September 24th’ Bioscience ClubhouseCT was the kick-off of the Fall season. The Study in New Haven provided a very fine venue, with pizza by Aerotek. The atmosphere at this ClubhouseCT felt like our community has joined together to give this event momentum. It was wonderful to feel the enthusiasm and interest in the room as Uday Khire shared his experiences using the platform of synthetic organic chemistry, especially in area of macrocyclics, to build two biotech companies, Cheminpharma, and its spin out Allomek. Clearly Uday is quite a determined entrepreneur, passionate about using chemistry to make new medicines. Carefully [...]

By |September 26th, 2014|Bioscience ClubhouseCT, Event Highlights|0 Comments

Dr. Bob Langer: On Disruptive Innovation

Yale’s recently established Center for Biomedical and Interventional Technology (CBIT), the mission of which is to foster greater innovation in medical technology, welcomed world-renowned engineer Dr. Bob Langer to speak before a full crowd at the Yale School of Medicine. An author on some 1,250 journal articles holding 1,050 patents, Dr. Langer is the David H. Koch Institute Professor at MIT, and the most highly cited engineer in history. Additionally, he has won over 220 major awards including the US National Medal of Science, US National Medal of Technology and Innovation, the Charles Stark Draper Prize and the Lemelson-MIT prize. [...]

By |September 23rd, 2014|Event Highlights|0 Comments

Challenges Facing Pharmaceutical R&D

At the first BioHaven of the season, CURE and Yale welcomed Dr. John LaMattina, former Senior Vice President of Pfizer Inc. and former President of Pfizer Global Research and Development. In that role, Dr. LaMattina oversaw the drug discovery and development efforts of over 12,000 colleagues in the United States, Europe and Asia. During his tenure as head of global R&D, Pfizer produced new treatments for cancer, smoking cessation, rheumatoid arthritis and AIDS. Dr. LaMattina spoke about how the major headwinds facing big pharma now, including lost revenues and decreased R&D productivity, ultimately affect all of us as patients. A [...]

By |September 15th, 2014|BioHaven, Event Highlights|0 Comments

Meet and Greet at the Town of Branford

On July 22nd, 2014, over 80 people from the Connecticut bioscience community gathered at the town of Branford for the CURE Bioscience ClubhouseCT “Meet and Greet” event, which featured eight Branford-based bioscience companies. Susan Froshauer, CEO of CURE, Usha Pillai, founder of the Bioscience ClubhouseCT, together with James Cosgrove, First Selectman of Branford, delivered the opening remarks. Froshauer and Pillai welcomed the attendees and described the CURE Bioscience ClubhouseCT’s mission of cultivating entrepreneurship and developing the start-up ecosystem in Connecticut. Cosgrove introduced the vibrant business environment in Branford and invited companies to move in to the town. Eight speakers then [...]

By |July 24th, 2014|Bioscience ClubhouseCT, Event Highlights|0 Comments

Fighting Against Heart Failure-The Start-up Story of Cornovus Pharmaceuticals

On June 16th, CURE Bioscience ClubhouseCT presented the start-up story of Cornovus Pharmaceuticals at UConn Cell and Genome Sciences Building. Faced with the rising prevalence of heart failure related to the aging population, Cornovus is committed to discovering and developing novel treatments to fight the battle against heart failure. James Heym, Senior Director of Cornovus, together with Julie Olson, CEO of Cornovus, spoke about the company’s scientific foundation and its business model at the event. Heart failure represents an end-stage phenotype of a number of different cardiovascular diseases. Despite its poor prognosis and significant healthcare cost due to hospitalization, there [...]

By |June 22nd, 2014|Bioscience ClubhouseCT, Event Highlights|0 Comments

The Impact of Big Data and Analytics on Pharmaceutical R&D-The SystaMedic Approach

Big data and analytics are a major catalyst in the pharmaceutical R&D revolution. The explosion of data created across the health care sectors provides a great opportunity for accelerating innovation. A compelling question currently facing the pharmaceutical industry is how to effectively utilize this data to create value. On May 12th, CURE Bioscience ClubhouseCT showcased SystaMedic’s novel cause-effect analysis platform that can efficiently predict the probability of R&D success. SystaMedic Inc., founded in 2009, consists of twelve former Pfizer leaders and scientists with an average of 20+ years pharmaceutical R&D experience with multi-disciplinary expertise including medicinal chemistry, prodrug design, synthesis [...]

By |May 22nd, 2014|Bioscience ClubhouseCT, Event Highlights|0 Comments

BioHaven Entrepreneur Series Featured Melinta Therapeutics

On April 29th at the Yale School of Medicine’s Anlyan Center, CURE BioHaven Entrepreneur Series presented “Melinta Therapeutics: The Road from the Lab to New Medicines”. As one of the co-founding scientists, Dr. Thomas Steitz spoke about the scientific side of Melinta (formerly known as Rib-X Pharmaceuticals). Dr. Steitz is the Sterling Professor of Molecular Biophysics and Biochemistry and a Howard Hughes Medical Institute Investigator at Yale University. He was awarded the Nobel Prize in Chemistry in 2009 for studies of the structure and function of the ribosome, a molecular machine that translates genetic information encoded in DNA into proteins [...]

By |May 20th, 2014|BioHaven|0 Comments

CURE Bioscience ClubhouseCT Presented the Start-up Story of Bioarray Therapeutics

On April 16th, CURE Bioscience ClubhouseCT invited Marcia Fournier, CEO of Bioarray Therapeutics, to speak at the spacious atrium on the Pfizer Groton campus. Aiming to tackle the “trial and error chemotherapy”problem and to help oncologists choose the right therapy, Bioarray develops personalized diagnostic tests to assess the effectiveness of breast cancer treatment for a given patient. As a molecular biologist with years of experience in cancer research, Marcia Fournier highlighted three essential elements of Bioarray: think differently, establish mutually beneficial partnerships and build a strong team. In contrast to most studies that focus on the unhealthy cancer patient populations, [...]

By |April 24th, 2014|Bioscience ClubhouseCT|0 Comments